Evaluation of the combined use of metronomic zoledronic acid and Coriolus versicolor in intratibial breast cancer mouse model
Date
2017
Authors
Ko, C.
Yue, G.
Gao, S.
Luo, K.
Siu, W.
Shum, W.
Shiu, H.
Lee, J.
Li, G.
Leung, P.
Editors
Advisors
Journal Title
Journal ISSN
Volume Title
Type:
Journal article
Citation
Journal of Ethnopharmacology, 2017; 204:77-85
Statement of Responsibility
Chun-Hay Ko, Grace Gar-Lee Yue, Si Gao, Ke-Wang Luo, Wing-Sum Siu, Wai-Ting Shum, Hoi-Ting Shiu, Julia Kin-Ming Lee, Gang Li, Ping-Chung Leung, Andreas Evdokiou, Clara Bik-San Lau
Conference Name
Abstract
Coriolus versicolor (CV) is a mushroom traditionally used for strengthening the immune system and nowadays used as immunomodulatory adjuvant in anticancer therapy. Breast cancer usually metastasizes to the skeleton, interrupts the normal bone remodeling process and causes osteolytic bone lesions. The aims of the present study were to evaluate its herb-drug interaction with metronomic zoledronate in preventing cancer propagation, metastasis and bone destruction.Mice inoculated with human breast cancer cells tagged with a luciferase (MDA-MB-231-TXSA) in tibia were treated with CV aqueous extract, mZOL, or the combination of both for 4 weeks. Alteration of the luciferase signals in tibia, liver and lung were quantified using the IVIS imaging system. The skeletal response was evaluated using micro-computed tomography (micro-CT). In vitro experiments were carried out to confirm the in vivo findings.Results showed that combination of CV and mZOL diminished tumor growth without increasing the incidence of lung and liver metastasis in intratibial breast tumor model. The combination therapy also reserved the integrity of bones. In vitro studies demonstrated that combined use of CV and mZOL inhibited cancer cell proliferation and osteoclastogenesis.These findings suggested that combination treatment of CV and mZOL attenuated breast tumor propagation, protected against osteolytic bone lesion without significant metastases. This study provides scientific evidences on the beneficial outcome of using CV together with mZOL in the management of breast cancer and metastasis, which may lead to the development of CV as adjuvant health supplement for the control of breast cancer.
School/Discipline
Dissertation Note
Provenance
Description
Access Status
Rights
© 2017 Elsevier B.V. All rights reserved.